Literature DB >> 27625036

Adelmidrol, a Palmitoylethanolamide Analogue, as a New Pharmacological Treatment for the Management of Inflammatory Bowel Disease.

Marika Cordaro1, Daniela Impellizzeri1, Enrico Gugliandolo1, Rosalba Siracusa1, Rosalia Crupi1, Emanuela Esposito1, Salvatore Cuzzocrea2.   

Abstract

Leukocyte infiltration, improved levels of intercellular adhesion molecule 1 (ICAM-1), and oxidative stress in the colon are the principal factors in inflammatory bowel disease. The goal of the current study was to explore the effects of adelmidrol, an analog of the anti-inflammatory fatty acid amide signaling molecule palmitoylethanolamide, in mice subjected to experimental colitis. Additionally, to clarify whether the protective action of adelmidrol is dependent on the activation of peroxisome proliferator-activated receptors (PPARs), we investigated the effects of a PPARγ antagonist, GW9662, on adelmidrol action. Adelmidrol (10 mg/kg daily, o.s.) was tested in a murine experimental model of colitis induced by intracolonic administration of dinitrobenzene sulfonic acid. Nuclear factor-κB translocation, cyclooxygenase-2, and phosphoextracellular signal-regulated kinase, as well as tumor necrosis factor-α and interleukin-1β, were significantly increased in colon tissues after dinitrobenzene sulfonic acid administration. Immunohistochemical staining for ICAM-1, P-selectin, nitrotyrosine, and poly(ADP)ribose showed a positive staining in the inflamed colon. Treatment with adelmidrol decreased diarrhea, body weight loss, and myeloperoxidase activity. Adelmidrol treatment, moreover, reduced nuclear factor-κB translocation, cyclooxygenase-2, and phosphoextracellular signal-regulated kinase expression; proinflammatory cytokine release; and the incidence of nitrotyrosine and poly(ADP)ribose in the colon. It also decreased the upregulation of ICAM-1 and P-selectin. Adelmidrol treatment produced a reduction of Bax and an intensification of Bcl-2 expression. This study clearly demonstrates that adelmidrol exerts important anti-inflammatory effects that are partly dependent on PPARγ, suggesting that this molecule may represent a new pharmacologic approach for inflammatory bowel disease treatment.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27625036     DOI: 10.1124/mol.116.105668

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  23 in total

1.  Adelmidrol protects against non-alcoholic steatohepatitis in mice.

Authors:  Mahitab Mohamed Nageeb; Monira Ismaeil Khatab; Ahmed Ahmed Abdel-Sameea; Noha Abbas Teleb
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-12-18       Impact factor: 3.000

2.  Rice Bran and Probiotics Alter the Porcine Large Intestine and Serum Metabolomes for Protection against Human Rotavirus Diarrhea.

Authors:  Nora Jean Nealon; Lijuan Yuan; Xingdong Yang; Elizabeth P Ryan
Journal:  Front Microbiol       Date:  2017-04-21       Impact factor: 5.640

3.  Palmitoylethanolamide Reduces Neuropsychiatric Behaviors by Restoring Cortical Electrophysiological Activity in a Mouse Model of Mild Traumatic Brain Injury.

Authors:  Francesca Guida; Serena Boccella; Monica Iannotta; Danilo De Gregorio; Catia Giordano; Carmela Belardo; Rosaria Romano; Enza Palazzo; Maria A Scafuro; Nicola Serra; Vito de Novellis; Francesco Rossi; Sabatino Maione; Livio Luongo
Journal:  Front Pharmacol       Date:  2017-03-06       Impact factor: 5.810

Review 4.  ALIAmides Update: Palmitoylethanolamide and Its Formulations on Management of Peripheral Neuropathic Pain.

Authors:  Ramona D'Amico; Daniela Impellizzeri; Salvatore Cuzzocrea; Rosanna Di Paola
Journal:  Int J Mol Sci       Date:  2020-07-27       Impact factor: 5.923

5.  Topical Application of Adelmidrol + Trans-Traumatic Acid Enhances Skin Wound Healing in a Streptozotocin-Induced Diabetic Mouse Model.

Authors:  Rosalba Siracusa; Daniela Impellizzeri; Marika Cordaro; Enrico Gugliandolo; Alessio F Peritore; Rosanna Di Paola; Salvatore Cuzzocrea
Journal:  Front Pharmacol       Date:  2018-08-23       Impact factor: 5.810

Review 6.  Cannabis, Cannabinoids, and the Endocannabinoid System-Is there Therapeutic Potential for Inflammatory Bowel Disease?

Authors:  Tim Ambrose; Alison Simmons
Journal:  J Crohns Colitis       Date:  2019-03-30       Impact factor: 9.071

Review 7.  Peroxisome Proliferator-Activated Receptors: Experimental Targeting for the Treatment of Inflammatory Bowel Diseases.

Authors:  Juan Decara; Patricia Rivera; Antonio Jesús López-Gambero; Antonia Serrano; Francisco Javier Pavón; Elena Baixeras; Fernando Rodríguez de Fonseca; Juan Suárez
Journal:  Front Pharmacol       Date:  2020-05-27       Impact factor: 5.810

8.  Hidrox® Counteracts Cyclophosphamide-Induced Male Infertility through NRF2 Pathways in a Mouse Model.

Authors:  Roberta Fusco; Angela Trovato Salinaro; Rosalba Siracusa; Ramona D'Amico; Daniela Impellizzeri; Maria Scuto; Maria Laura Ontario; Roberto Crea; Marika Cordaro; Salvatore Cuzzocrea; Rosanna Di Paola; Vittorio Calabrese
Journal:  Antioxidants (Basel)       Date:  2021-05-14

9.  Hidrox® Roles in Neuroprotection: Biochemical Links between Traumatic Brain Injury and Alzheimer's Disease.

Authors:  Marika Cordaro; Angela Trovato Salinaro; Rosalba Siracusa; Ramona D'Amico; Daniela Impellizzeri; Maria Scuto; Maria Laura Ontario; Roberto Crea; Salvatore Cuzzocrea; Rosanna Di Paola; Roberta Fusco; Vittorio Calabrese
Journal:  Antioxidants (Basel)       Date:  2021-05-20

10.  Hidrox® and Chronic Cystitis: Biochemical Evaluation of Inflammation, Oxidative Stress, and Pain.

Authors:  Ramona D'Amico; Angela Trovato Salinaro; Marika Cordaro; Roberta Fusco; Daniela Impellizzeri; Livia Interdonato; Maria Scuto; Maria Laura Ontario; Roberto Crea; Rosalba Siracusa; Salvatore Cuzzocrea; Rosanna Di Paola; Vittorio Calabrese
Journal:  Antioxidants (Basel)       Date:  2021-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.